Clinical trial NCT05154604: A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours
Official title: A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1921 in Subjects With Advanced Malignant Solid Tumour .
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Advanced Solid Tumours
Lead sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2021-12-13
Enrollment: 156
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To assess the safety and tolerability of SHR-A1921 in patients with advanced solid tumours, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D) of SHR-A1921


Eligibility criteria: Inclusion Criteria:

1. Voluntary participation and written informed consent；
2. Aged 18-75 years (inclusive), males and females;
3. Consents to provide tumor tissue samples;
4. Subjects must have histologically or clinically confirmed advanced and/or metastatic malignancies for which failure of standard treatment or lack of effective standard treatment;
5. At least one measurable lesion according to RECIST v1.1;
6. ECOG score of 0-1;
7. Expected survival ≥ 12 weeks;
8. Adequate bone marrow reserve and organ function ；
9. For female patients of childbearing potential or male patients with partners of childbearing potential who are not sterilized by surgical operations, they are required to use a medically approved contraceptive measure during the study treatment period and within 3 months after the end of the study treatment; For female patients of childbearing potential who are not sterilized by surgical operations, they must have a negative serum HCG test result within 72 h prior to study enrollment; and they must not be in the lactation period;

Exclusion Criteria:

1. Known and untreated central nervous system (CNS) or leptomeningeal metastases;
2. Macrovascular invasion based on imaging;
3. Cancerous ascites, pleural effusion or pericardial effusion with clinical symptoms;
4. Has a history of a second malignancy;
5. History of immunodeficiency disease or organ transplant;
6. Uncontrolled cardiac diseases or symptoms;
7. Has a history of non-infectious ILD/pneumonitis that required steroids, or has current ILD/pneumonitis;
8. Has a history of active chronic enteritis 6 weeks prior to the initiation of the study treatment or intestinal obstruction, gastrointestinal perforation 3 months prior to the initiation of the study treatment;
9. Has a history of Grade≥2 bleeding 4 weeks prior to the initiation of the study treatment or is current receiving anticoagulation therapy;
10. Subjects with active hepatitis B or active hepatitis C;
11. Subjects who have received systemic anti-tumor treatments 4 weeks prior to the initiation of the study treatment.
12. Has unresolved toxicities from previous anticancer therapy.
13. Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients of SHR-A1921;
14. Subjects with other potential factors that may affect the study results or result in the premature discontinuation as determined by the investigator, such as alcoholism, drug abuse, other serious diseases (including mental illness) requiring concomitant treatment, serious laboratory abnormalities, or family or social factors that could affect the safety of the patients.

Primary outcomes:
measure: Dose Limited Toxicity (DLT)
timeFrame: 21 Days (first cycle)
measure: Maximum Tolerable Dose (MTD)
timeFrame: 21 Days (first cycle)
measure: Recommended phase II dose (RP2D)
timeFrame: Screening up to dose escalation and expansion study completion, appropriately to 1 year
measure: Adverse Events
timeFrame: Screening up to study completion, an average of 1 year
Secondary outcomes:
measure: Time to reach maximum concentration (Tmax) of SHR-A1921、total antibody
timeFrame: Screening up to end of treatment, an average of 1 year
measure: Maximum concentration (Cmax) of SHR-A1921、total antibody
timeFrame: Screening up to end of treatment, an average of 1 year
measure: Area under the concentration-time curve from time zero to the time of the last quantifiable time point t (AUC0-t) of SHR-A1921、total antibody
timeFrame: Screening up to end of treatment, an average of 1 year
measure: Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-t) of SHR-A1921、total antibody
timeFrame: Screening up to end of treatment, an average of 1 year
measure: Terminal half-life (t1/2) of SHR-A1921、total antibody
timeFrame: Screening up to end of treatment, an average of 1 year
measure: Total body clearance (CL) of SHR-A1921、total antibody
timeFrame: Screening up to end of treatment, an average of 1 year
measure: Volume of distribution at steady state (Vss) of SHR-A1921、total antibody
timeFrame: Screening up to end of treatment, an average of 1 year
measure: Mean residence time (MRT) of SHR-A1921、total antibody
timeFrame: Screening up to end of treatment, an average of 1 year
measure: Maximum steady-state drug concentration during a dosage interval (Css, max) of SHR-A1921、total antibody
timeFrame: Screening up to end of treatment, an average of 1 year
measure: Minimum steady-state drug concentration during a dosage interval (Css, min) of SHR-A1921、total antibody
timeFrame: Screening up to end of treatment, an average of 1 year
measure: Accumulation ratio (Rac) of SHR-A1921、total antibody
timeFrame: Screening up to end of treatment, an average of 1 year
measure: Anti-drug antibody(ADA) level of SHR-A1921
timeFrame: Screening up to 90 days after the last dose, an average of 1 year
measure: Objective Response Rate (ORR) assessed by site investigator as per RECIST 1.1
timeFrame: Screening up to study completion, an average of 1 year
measure: Duration of Response (DoR) assessed by site investigator as per RECIST 1.1
timeFrame: Screening up to study completion, an average of 1 year
measure: Disease Control Rate (DCR) assessed by site investigator as per RECIST 1.1
timeFrame: Screening up to study completion, an average of 1 year
measure: Progression-Free Survival (PFS) assessed by site investigator as per RECIST 1.1
timeFrame: Screening up to study completion, an average of 1 year
measure: Overall Survival (OS)
timeFrame: Screening up to study completion, an average of 1 year
Other outcomes:
Locations:
Study officials:
References: